Placebo News and Research

RSS

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Researchers study placebo effect in nausea treatment at the molecular level

The molecular bases of the placebo effect are poorly understood. A team led by Ludwig-Maximilians-Universitaet in Munich researcher Karin Meissner has now studied the phenomenon in the context of nausea, and identified specific proteins that correlate with its favorable impact.

28 Sep 2020

Study may explain why hormone therapy slows progression of heart disease

As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

28 Sep 2020

New drug offers hope for young boys with Duchenne muscular dystrophy

A new drug offers hope for young boys with the progressive neuromuscular disease Duchenne muscular dystrophy (DMD) by potentially offering an alternative to high-dose glucocorticoids that have significant side effects.

25 Sep 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes

A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels

25 Sep 2020

New antibodies protect mice against lethal infections of influenza B virus

Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.

24 Sep 2020

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

23 Sep 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.

22 Sep 2020

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

21 Sep 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

Non-invasive neurotechnology can improve insomnia symptoms and autonomic function

For people with chronic insomnia, a good night's sleep is elusive. But what if insomnia symptoms could be alleviated by simply listening to one's own brainwaves?

17 Sep 2020

Researchers are testing the effectiveness of multiple treatments to prevent COVID-19

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2020

Phosphate binder drug does not reduce heart disease risk in people with chronic kidney disease

Following a large-scale clinical trial, researchers have found that lanthanum carbonate does not reduce the risk of cardiovascular disease developing in patients with chronic kidney disease.

14 Sep 2020

International trial of blood thinners for COVID-19 treatment begins

These trials, known as ACTIV-4 Antithrombotics, are part of the three planned adaptive trials in this area of clinical research, included in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative. They are expected to yield new data on the safety and efficacy of these drugs in the treatment of active and convalescent COVID-19 treatment.

13 Sep 2020

Measuring heart rate changes to detect depression risk

For the first time doctors have shown that measuring changes in 24-hour heart rate can reliably indicate whether or not someone is depressed.

11 Sep 2020

Placebo News and Research

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

Researchers study placebo effect in nausea treatment at the molecular level

Study may explain why hormone therapy slows progression of heart disease

New drug offers hope for young boys with Duchenne muscular dystrophy

New trial tests combination antibody treatment for preventing COVID-19 illness

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes

New antibodies protect mice against lethal infections of influenza B virus

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

Non-invasive neurotechnology can improve insomnia symptoms and autonomic function

Researchers are testing the effectiveness of multiple treatments to prevent COVID-19

Phosphate binder drug does not reduce heart disease risk in people with chronic kidney disease

International trial of blood thinners for COVID-19 treatment begins

Measuring heart rate changes to detect depression risk

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News